Ceftezole

As a first-generation cephalosporin anti-infective drug, ceftezole exerts a bactericidal effect by inhibiting the biosynthesis of bacterial cell walls, and has good antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria. It is clinically mainly used to treat respiratory system infections, urinary system infections, sepsis, peritonitis, etc. caused by sensitive bacteria, and is applicable to adult patients and pediatric patients who have no allergic reaction to this class of drugs. Compared with other first-generation cephalosporins, it has lower nephrotoxicity and better applicability to patients with mild renal insufficiency.

The global ceftezole market size was approximately USD 210 million in 2023, and is expected to grow steadily at a compound annual growth rate of 3.2% from 2024 to 2029. The growth momentum mainly comes from the continuous release of demand for anti-infective drugs in primary medical institutions. The domestic market is currently dominated by the supply of generic drugs, and API manufacturers are concentrated in North China and East China. The overall competitive landscape is relatively stable, and the winning bid prices in centralized procurement tend to be reasonable, without significant price fluctuations.

The original research enterprise of ceftezole is Takeda Pharmaceutical Company Limited of Japan, with the original brand name Ceftezole, and the core compound patent expired in the 1980s. The main dosage form currently on the market is ceftezole sodium for injection, with common specifications including 0.5g and 1.0g, and the original formulation has been included in the FDA Reference Listed Drug Catalog. In terms of the domestic market, as of the retrieval time point, there are a total of 12 A-status registration numbers for ceftezole APIs, and more than 30 manufacturers have obtained approval for ceftezole sodium for injection preparations, realizing fully localized supply of this variety. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of ceftezole impurity reference standards. The R&D team has completed the structural confirmation and purity calibration of all impurities. The products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most impurities are available directly from stock, and orders placed before 16:00 can be shipped on the same day, which can fully meet the needs of pharmaceutical enterprises in R&D and production scenarios such as impurity research and quality control.